reports
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Y...
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raised to $238-$242 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlig...
ING Groep N.V.: 1 director
A director at ING Groep N.V. sold 2,500 shares at 16.000EUR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Moody's Ratings affirms EQUATE's Baa2 issuer rating; outlook changed t...
Moody's Ratings (Moody's) has today affirmed the Baa2 long-term issuer rating of EQUATE Petrochemical Co. K.S.C.C ("EQUATE") as well as the (P)Baa2 backed senior unsecured ratings on the existing GMTN and sukuk programmes established under EQUATE Petrochemical B.V., MEGlobal Canada ULC and EQUATE Su...
- Daniel Slater
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces Voting Results on Election of Directors SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of the Company held on May 7, 2024 (the “Annual Meeting”), shareholders voted in favour of all items of business put forth by the Company, including the election of the directors by a majority of the votes cast by shareholders present or represented by proxy. The Annual Meeting was held in a virtual-only format, for those who wer...
Shijiazhuang Kelin Electric Co Ltd: 2 directors
Two Directors at Shijiazhuang Kelin Electric Co Ltd bought 307,700 shares at between 27.502CNY and 27.535CNY. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...
Kendrion N.V.: 1 director
A director at Kendrion N.V. bought 7,600 shares at 13.300EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Chocoladefabriken Lindt & Sprungli AG: 1 director
A director at Chocoladefabriken Lindt & Sprungli AG sold 240 shares at 10,603.000CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Confer...
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T. To register for the live event, please . The webcast will also be available on the Company’s website on the page in the “Investors” section. An archived webcast...
TKB-Geschäftsbericht 2023 verabschiedet
Thurgauer Kantonalbank / Schlagwort(e): Sonstiges TKB-Geschäftsbericht 2023 verabschiedet 08.05.2024 / 13:30 CET/CEST Medienmitteilung vom 8. Mai 2024 An seiner heutigen Sitzung hat der Thurgauer Grosse Rat den Geschäfts- und Nachhaltigkeitsbericht der Thurgauer Kantonalbank (TKB) genehmigt. Somit ist auch die Dividendenausschüttung für das Geschäftsjahr 2023 definitiv. Diese wurde auf 3,30 Franken pro Partizipationsschein erhöht. Der Thurgauer Grosse Rat hat an seiner Sitzung vom 8. Mai 2024 den Jahresbericht und die Jahresrechnung 2023 der TKB genehmigt. Die Revisionsstelle PWC w...
EQS-News: Vossloh receives another major order to supply rail fastenin...
EQS-News: Vossloh Aktiengesellschaft / Key word(s): Incoming Orders Vossloh receives another major order to supply rail fastening systems in China 08.05.2024 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Vossloh receives another major order to supply rail fastening systems in China Systems serve the construction of two high-speed lines The order is valued at the equivalent of around €40 million Deliveries planned from 2025 Werdohl, May 8, 2024. Vossloh has once again been awarded a contract to supply rail fastening systems in ...
EQS-News: Vossloh erhält erneut Großauftrag zur Lieferung von Schienen...
EQS-News: Vossloh Aktiengesellschaft / Schlagwort(e): Auftragseingänge Vossloh erhält erneut Großauftrag zur Lieferung von Schienenbefestigungssystemen in China 08.05.2024 / 13:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Vossloh erhält erneut Großauftrag zur Lieferung von Schienenbefestigungssystemen in China Systeme dienen dem Bau von zwei Hochgeschwindigkeitsstrecken Auftragswert beträgt umgerechnet rund 40 Mio.€ Auslieferungen ab 2025 geplant Werdohl, 8. Mai 2024. Vossloh hat erneut den Zuschlag für die Lieferung von Sch...
Moody's Ratings assigns B3 CFR to Advania; outlook stable
Moody's Ratings (Moody's) has today assigned a B3 corporate family rating (CFR) and B3-PD probability of default rating (PDR) to Ainavda Parentco AB (Advania or the company). Concurrently, Moody's has assigned B3 ratings to the planned €375 million backed senior secured term loan B1, €250 million eq...
MasterCraft Boat Holdings, Inc. Reports Results for Fiscal 2024 Third ...
MasterCraft Boat Holdings, Inc. Reports Results for Fiscal 2024 Third Quarter VONORE, Tenn., May 08, 2024 (GLOBE NEWSWIRE) -- MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The overview, commentary, and results provided herein relate to our continuing operations. Overview: Net sales for the third quarter were $95.7 million, down 42.6% from the prior-year periodNet income from continuing operations was $3.8 million, or $0.23 per diluted shareDiluted Adjusted Net Income per share, a non-GAAP measure...
Kornit Digital Reports First Quarter 2024 Results
Kornit Digital Reports First Quarter 2024 Results First quarter revenues of $43.8 million, in line with previous guidanceFirst quarter GAAP net loss of $13.2 million; non-GAAP net loss of $5.3 millionGenerated positive cash flow from operations for the first quarter of 2024Successfully concluded Apollo beta with all three customers and built a healthy pipelineSignificant interest from new and existing customers on the all-inclusive click (“AIC”) model ROSH-HA`AYIN, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a worldwide market ...
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficam...
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in ...
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-...
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in 2H 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetic...
Genie Energy Announces First Quarter 2024 Results
Genie Energy Announces First Quarter 2024 Results Revenue increased to $119.7 Million and Gross Profit Climbed to $33.8 Million - Both Record First Quarter Levels Income from Operations of $9.8 million, Adjusted EBITDA1 of $11.7 Million and Earnings per Diluted Share of $0.30 Repurchased 250,000 Shares of Class B Common Stock Newark, NJ, May 08, 2024 (GLOBE NEWSWIRE) -- Genie Energy, Ltd. (NYSE: GNE), a leading retail energy and renewable energy solutions provider, today announced results for the first quarter of 2024. Michael Stein, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.